ID   CEM/VLB100
AC   CVCL_3932
SY   CEM-VLB100; CEM/VLB 100; CEM/VBL 100; CEM-VBL100
DR   BTO; BTO:0005155
DR   cancercelllines; CVCL_3932
DR   ChEMBL-Cells; CHEMBL3988441
DR   Cosmic; 922676
DR   PubChem_Cell_line; CVCL_3932
DR   Wikidata; Q54809282
RX   PubMed=571759;
RX   PubMed=2888532;
RX   PubMed=3469013;
RX   PubMed=9557624;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI:27375; Vincaleukoblastine (Vinblastine).
CC   Sequence variation: Gene fusion; HGNC; 13222; BCL11B + HGNC; 2488; NKX2-5; Name(s)=NKX2.5-BCL11B (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg465Cys (c.1393C>T); ClinVar=VCV000376414; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 3765; FLT3; Simple; p.Ala627Thr (c.1879G>A); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Leu1593_Arg1594insProArgLeuProHisAsnSerSerPheHisPheLeu (c.4780_4781ins36); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Pro2412Thr (c.7234C>A); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Heterozygous (from parent cell line).
CC   Caution: Seems to be interchangeably called VLB100 or VBL100.
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
CC   Cell type: T-cell; CL=CL_0000084.
DI   NCIt; C7953; Childhood T acute lymphoblastic leukemia
DI   ORDO; Orphanet_99861; Precursor T-cell acute lymphoblastic leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0207 ! CCRF-CEM
SX   Female
AG   3Y11M
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 27
//
RX   PubMed=571759;
RA   Beck W.T., Mueller T.J., Tanzer L.R.;
RT   "Altered surface membrane glycoproteins in Vinca alkaloid-resistant
RT   human leukemic lymphoblasts.";
RL   Cancer Res. 39:2070-2076(1979).
//
RX   PubMed=2888532;
RA   Beck W.T., Cirtain M.C., Danks M.K., Felsted R.L., Safa A.R.,
RA   Wolverton J.S., Suttle D.P., Trent J.M.;
RT   "Pharmacological, molecular, and cytogenetic analysis of 'atypical'
RT   multidrug-resistant human leukemic cells.";
RL   Cancer Res. 47:5455-5460(1987).
//
RX   PubMed=3469013;
RA   Danks M.K., Yalowich J.C., Beck W.T.;
RT   "Atypical multiple drug resistance in a human leukemic cell line
RT   selected for resistance to teniposide (VM-26).";
RL   Cancer Res. 47:1297-1301(1987).
//
RX   PubMed=9557624; DOI=10.1038/sj.leu.2400976;
RA   Mattii L., Barale R., Petrini M.;
RT   "Use of the comet test in the evaluation of multidrug resistance of
RT   human cell lines.";
RL   Leukemia 12:627-632(1998).
//